CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 254 enrolled
Drug / intervention
Fluticasone 44 mcg +1 moredrug
Likely dose
Fluticasone 44 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02066129
NCT02066129Phase 3Completed
CompareCT.gov

Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations

Milton S. Hershey Medical Center·interventional·Posted Feb 19, 2014·Updated Jul 11, 2018

In Brief

A Phase 3 clinical trial evaluating Fluticasone 44 mcg and Fluticasone 220 mcg for Asthma. Completed, enrolled 254 participants across 18 sites.

Detailed Summary

The objective of this study is to determine whether, in children receiving low-dose inhaled corticosteroids (ICS), quintupling the dose of inhaled corticosteroids at the onset of symptoms previously associated with upper respiratory illnesses and subsequent asthma exacerbations reduces the rate of severe asthma exacerbations treated with oral corticosteroids.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 19, 2014
Enrollment StartJul 1, 2014
Primary CompletionApr 21, 2017
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.4 years ago

Interventions

Fluticasone 44 mcgdrug

Fluticasone is an inhaled corticosteroid

Fluticasone 220 mcgdrug

Fluticasone is an inhaled corticosteroid